Literature DB >> 28579683

Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data.

Susan Shamimi-Noori1, Carin F Gonsalves1, Colette M Shaw1.   

Abstract

Metastatic liver disease is a major cause of cancer-related morbidity and mortality. Surgical resection is considered the only curative treatment, yet only a minority is eligible. Patients who present with unresectable disease are treated with systemic agents and/or locoregional therapies. The latter include thermal ablation and catheter-based transarterial interventions. Thermal ablation is reserved for those with limited tumor burden. It is used to downstage the disease to enable curative surgical resection, as an adjunct to surgery, or in select patients it is potentially curative. Transarterial therapies are indicated in those with more diffuse disease. The goals of care are to palliate symptoms and prolong survival. The indications and supporting data for thermal ablation and transarterial interventions are reviewed, technical and tumor factors that need to be considered prior to intervention are outlined, and finally several cases are presented.

Entities:  

Keywords:  chemoembolization; interventional radiology; liver metastases; locoregional therapy; radioembolization; thermal ablation

Year:  2017        PMID: 28579683      PMCID: PMC5453777          DOI: 10.1055/s-0037-1602712

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  153 in total

1.  Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres.

Authors:  Andrew S Kennedy; David Ball; Steven J Cohen; Michael Cohn; Douglas M Coldwell; Alain Drooz; Eduardo Ehrenwald; Samir Kanani; Steven C Rose; Charles W Nutting; Fred M Moeslein; Michael A Savin; Sabine Schirm; Samuel G Putnam; Navesh K Sharma; Eric A Wang
Journal:  J Gastrointest Oncol       Date:  2015-04

2.  Transarterial chemoembolisation (TACE) with gemcitabine: phase II study in patients with liver metastases of breast cancer.

Authors:  Katrin Eichler; Silke Jakobi; Tatjana Gruber-Rouh; Renate Hammerstingl; Thomas J Vogl; Stephan Zangos
Journal:  Eur J Radiol       Date:  2013-09-01       Impact factor: 3.528

3.  Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors.

Authors:  Katrin Hoffmann; Clemens Franz; Ulf Hinz; Peter Schirmacher; Christian Herfarth; Michael Eichbaum; Markus W Büchler; Peter Schemmer
Journal:  Ann Surg Oncol       Date:  2010-02-09       Impact factor: 5.344

4.  Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma.

Authors:  T Shibata; T Niinobu; N Ogata; M Takami
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

5.  Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: a retrospective analysis.

Authors:  Xiao Feng Duan; Na Na Dong; Ti Zhang; Qiang Li
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-26       Impact factor: 4.553

6.  Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients.

Authors:  Gowthaman Gunabushanam; Sanjay Sharma; Sanjay Thulkar; Deep N Srivastava; Goura Kishor Rath; Pramod Kumar Julka; Sushma Bhatnagar
Journal:  J Vasc Interv Radiol       Date:  2007-01       Impact factor: 3.464

Review 7.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

8.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.

Authors:  Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

9.  Very long-term prognosis of patients with malignant uveal melanoma.

Authors:  Emma Kujala; Teemu Mäkitie; Tero Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-11       Impact factor: 4.799

10.  A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma.

Authors:  Juliane Schelhorn; Heike Richly; Marcus Ruhlmann; Thomas C Lauenstein; Jens M Theysohn
Journal:  Acta Radiol Open       Date:  2015-04-06
View more
  6 in total

1.  Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor receptor siRNA enhanced tumor-suppressing effect on liver cancer.

Authors:  Zhili Wen; Yuliang Feng; Youwen Hu; Lingyan Lian; Hongyan Huang; Li Guo; Shanwen Chen; Qian Yang; Moran Zhang; Lijun Wan; Kedong Xu; Xiaohua Yan
Journal:  Aging (Albany NY)       Date:  2021-01-13       Impact factor: 5.682

2.  Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis.

Authors:  Sven H Loosen; Max Schulze-Hagen; Mihael Vucur; Joao Gorgulho; Pia Paffenholz; Fabian Benz; Raphael Mohr; Münevver Demir; Alexander Wree; Christiane Kuhl; Christian Trautwein; Frank Tacke; Philipp Bruners; Tom Luedde; Christoph Roderburg
Journal:  JGH Open       Date:  2021-02-01

3.  A novel multimodal nanoplatform for targeting tumor necrosis.

Authors:  Xiangjun Han; Oleh Taratula; Anna St Lorenz; Abraham S Moses; Hassan A Albarqi; Younes Jahangiri; Qirun Wu; Ke Xu; Olena Taratula; Khashayar Farsad
Journal:  RSC Adv       Date:  2021-09-15       Impact factor: 3.361

4.  IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies.

Authors:  Sven H Loosen; Maximilian Schulze-Hagen; Catherine Leyh; Fabian Benz; Mihael Vucur; Christiane Kuhl; Christian Trautwein; Frank Tacke; Philipp Bruners; Christoph Roderburg; Tom Luedde
Journal:  Int J Mol Sci       Date:  2018-06-14       Impact factor: 5.923

5.  Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies.

Authors:  Theresa H Wirtz; Sven H Loosen; Max Schulze-Hagen; Joao Gorgulho; Jennis Kandler; Markus Joerdens; Münevver Demir; Raphael Mohr; Philipp Bruners; Christiane Kuhl; Christian Trautwein; Marie-Luise Berres; Frank Tacke; Tom Luedde; Christoph Roderburg
Journal:  Clin Transl Sci       Date:  2021-07-19       Impact factor: 4.689

6.  Long-Term Comparative Study on the Local Tumour Control of Different Ablation Technologies in Primary and Secondary Liver Malignancies.

Authors:  Attila Kovács; Peter Bischoff; Hathal Haddad; Willi Zhou; Susanne Temming; Andreas Schäfer; Hannah Spallek; Lucas Kaupe; György Kovács; Michael Pinkawa
Journal:  J Pers Med       Date:  2022-03-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.